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Abstract
In the field of cell therapy, allogenic human mesenchymal stromal cells (hMSCs) are 
often used in clinical trials, creating a demand for cell mass production using efficient 
dynamic bioreactor systems. As an advanced therapy medicinal product (ATMP), such 
cells should meet certain special requirements, including product specifications requir-
ing a production process compatible with good manufacturing practice (GMP). The 
development of processes in which the cells are the product therefore remains a signifi-
cant challenge. This chapter describes the requirements at different steps in the upstream 
and downstream phases of such dynamic processes. Potential solutions are presented 
and future prospects are discussed, including the selection of media and carriers for 
the strictly adherent growing cells, allowing efficient cell adhesion and detachment. 
Strategies for dynamic cultivation in bioreactors are described in detail for fixed‐bed and 
stirred‐tank reactors based on GMP requirements and the integration of process analyti-
cal technology (PAT). Following cell harvest, separation and purification, the formulation 
and storage of the product are also described. Finally, the chapter covers important cell 
quality characteristics necessary for the approval of ATMPs.
Keywords: hMSC, cell expansion, stirred‐tank reactor, microcarrier, fixed‐bed reactor, 
PAT, GMP, ATMP, cell harvest, formulation, storage, quality approval
1. Introduction
Intensive research in the field of regenerative medicine has resulted in a large number of 
clinical trials over the last few years. The unique characteristics and differentiation pathways 
of human mesenchymal stem/stromal cells (hMSCs) make them promising candidates for 
future therapeutic strategies. There is a great interest in these cells because they can migrate 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
to injured tissues following implantation or intravenous injection, and they have anti‐inflam-
matory and regenerative capacity due to the release of cytokines, specific growth factors and 
other bioactive molecules. In addition to non‐differentiated cells, the differentiation of hMSCs 
into osteocytes, chondrocytes, adipocytes, tenocytes and muscle cells [1, 2] may allow the 
treatment of patients with bone and cartilage diseases, gastrointestinal diseases, diabetes, 
graft‐versus‐host diseases and limbal stem‐cell deficiency [3–6]. The application of immu-
nomodulatory hMSCs may involve autologous cells (isolated from the patient and used in 
personalized therapy) or allogenic cells (isolated from another individual, then expanded and 
used in the patient). Allogenic cells allow off‐the‐shelf treatment for indications affecting a 
large number of patients. In addition to primary hMSCs, which can be isolated from bone 
marrow, adipose tissue and the umbilical cord, the genetically modified and immortalized 
cell line hMSC‐TERT achieves higher passaging numbers while retaining the differentiation 
potential of primary cells [7, 8]. ClinicalTrials.gov currently lists 51 clinical trials specifically 
involving autologous hMSCs, 32 of which are ongoing, whereas 67 studies are listed for allo-
genic hMSCs, 56 of which are ongoing (accessed May 9, 2016). Since 2005, the number of 
clinical trials has increased continuously, the majority using allogenic cells [9]. These trials 
have shown that cell‐dose‐dependent efficacy requires a minimum of 1.5–6 × 107 cells per 
dose, depending on the indication [10, 11]. Human cells are classed as advanced therapy 
medicinal products (ATMPs). Only four ATMPs are currently authorized, which may reflect 
the lack of suitable production processes [12]. This reveals the need for robust and efficient 
biomass expansion processes for adherent growing hMSCs that yield a high‐quality product. 
The development of dynamic processes for sensitive, adherent growing cells is challenging 
because several requirements discussed in this chapter must be fulfilled to mimic in vivo con-
ditions. This article focuses on dynamic processes for primary bone marrow‐derived hMSCs 
and the hMSC‐TERT cell line for allogenic applications of non‐differentiated cells.
2. Requirements for stem cell expansion
2.1. Cells as a product
In contrast to biopharmaceutical production processes in which the cell synthesizes the prod-
uct, in the field of cell therapy, the cells are the product. Like any other medical product, cells 
must be approved by the competent authorities, i.e., the European Medicines Agency (EMA) 
in Europe or the Food and Drug Administration (FDA) in the USA. Medicines based on genes, 
cells or tissues are usually defined as ATMPs, a category that includes both hMSCs and the 
hMSC‐TERT cell line. ATMPs are subject to special guidelines in addition to the standard 
good manufacturing practice (GMP) requirements. In the EU, such products must be compli-
ant with Regulation 1394/2007, guideline EMEA/CHMP/410869/2006, Directives 2004/23/EC, 
2006/17/EC, 2006/86/EC and the revised guideline EMA/CAT/600280/2010. In the USA, such 
products must be compliant with the FDA Code of Federal Regulations (CFRs) covering inves-
tigational new drug (IND) applications (21 CFR 312), biological regulations (21 CFR 600) and 
GMP (21 CFR 211) [13–15]. The International Society for Stem Cell Research (ISSCR) published 
its updated “Guidelines for Stem Cell Research and Clinical Translation” in May 2016 [16] 
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with commentaries on manufacturing, safety and efficacy to provide standard guidelines and 
recommendations.
In addition to the regulatory framework, different societies and institutes have listed prod-
uct characteristics that must be fulfilled [17]. One definition of hMSCs is provided by the 
International Society for Cell Therapy (ISCT) in their “minimal criteria for defining multipotent 
mesenchymal stromal cells” [18]. These criteria include the identity of cells, which is character-
ized by the following cell surface markers: positive expression (>95%) of CD105, CD73 and 
CD90, and no expression (<2%) of CD45, CD34, CD14 or CD11b, CD79α or CD19 and HLA class 
II. Also included in the ISCT definition is the adherence to plastic surfaces and the differentia-
tion capacity in vitro into osteoblasts, adipocytes and chondroblasts. These characteristics must 
be defined and extended specifically for each cell line depending on its source [19].
To meet these regulatory demands and retain the defined cell characteristics, extreme care 
must be taken during process development in a dynamic system to achieve the highest final 
product quality. Only a few aspects can be covered in this chapter, showing the complexity 
of the issue. Figure 1 shows the steps in a general production process including the various 
aspects that must be addressed.
Different aspects during each step determine the final product quality and process efficiency 
by affecting cell viability, potency, identity and safety. Each aspect summarized in Figure 1 
must also be regarded in the context of GMP, which provides general guidance rather than 
Figure 1. General overview of a dynamic production process for hMSCs including various aspects that influence the 
final product quality.
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detailed instruction. Briefly, the processes must ensure the quality of the product at each step 
and part of the system, as well as the final product. The basic materials should be chemically 
defined and proven to be within specifications. The quality and purity of all substances must 
be ensured. Robustness, reproducibility and efficiency must be shown using closed control 
systems to confirm quality, safety and efficacy throughout the process. The documentation 
required for each quality‐relevant step is usually completed using standard operating proce-
dures [20]. Process analytical technology (PAT) is one tool that can be used to ensure process 
quality based on the online and offline monitoring of different parameters [21]. Further exam-
ples of GMP include the requirement of animal‐free materials, closed production systems and 
system validation that confirms the separation of different production processes, favoring 
disposable equipment. The biological source is one of the major factors that determine process 
success. The age and health of the human donor as well as the tissue of origin affect cell qual-
ity attributes. For both primary hMSCs and hMSC‐TERT cells, the number of passages has a 
major influence on the final product quality and must be as low as possible [22].
2.2. Process requirements—upstream
2.2.1. Stem cell media
The maintenance of proliferating hMSCs requires special growth media, typically a basal 
medium comprising salts, glucose, amino acids and a buffer system supplemented with 
serum. The latter is routinely used because it contains proteins, adhesion factors, vitamins, 
growth factors, hormones, fatty acids and lipids that promote cell adhesion and attachment 
(e.g., to collagen, fibronectin, laminin and vitronectin), which is required for in vitro cell 
proliferation [23]. Important variables include the concentration of each ingredient, and the 
osmolality, buffering capacity, conductivity, substrate availability and stability (especially 
thermostability) of the medium. Serum constitutes a risk when hMSCs are produced for clini-
cal applications under GMP and also increases the complexity of downstream processing. 
Serum should be avoided because it is derived from animals, thus increasing the risk of con-
tamination (e.g., with viruses) and immunogenicity, and its complexity introduces unknown 
variables that make process standardization difficult to achieve.
To eliminate serum from stem cell production processes, several defined serum‐free formula-
tions have been developed. According to one classification system [24], a “defined medium” 
can be further divided into the following categories:
 – Serum‐free medium (SFM) containing a broad range of supplementary hormones, growth 
factors, proteins and polyamines, derived from bovine or human sources
 – Protein‐free medium (PFM) containing peptide fragments from enzymatic or acid hydro-
lysis of animal or plant source proteins
 ° PFM variant A containing human serum albumin, human transferrin, human insulin 
and animal‐derived lipids
 ° PFM variant B, also known as xeno‐free medium (XFM) containing human serum albu-
min, human transferrin, human insulin and chemically defined lipids
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 – Recombinant xeno‐free medium (recXFM) containing either recombinant proteins, hor-
mones and compounds or chemically defined lipids
 – Chemically defined medium (CDM)—a protein‐free basal medium containing low‐
molecular‐weight components, synthetic peptides or hormones, and a few recombinant 
or synthetic versions of proteins.
In‐house serum‐free media for hMSCs have been reported in several studies, often contain-
ing additional factors such as bovine/human serum albumin, insulin, transferrin, hormones 
(e.g., progesterone, hydrocortisone and estradiol), growth factors (e.g., bFGF, TGFβ, EGF or 
PDGF) or heparin [25–28]. The list of commercially available chemically defined, protein‐free, 
xeno‐free and serum‐free is constantly increasing [29] as discussed in recent reviews [30, 31].
2.2.2. Growth surfaces
The characteristics of the growth surface have a major impact on the cultivation of hMSCs, 
especially in the context of production processes. The attachment, spreading and proliferation 
of these adherent cells are strongly influenced by the growth surface and the corresponding 
cell‐surface interactions. These interactions can induce signaling pathways that are involved 
in regulating important cellular processes including cell migration, gene expression, cell sur-
vival, tissue organization and differentiation [32–34].
In dynamic bioreactor systems for adherent cells, microcarriers provide the growth surface in 
suspension or as a bed. The choice of an appropriate microcarrier, which not only supports 
attachment and growth but also allows efficient detachment without losing viability, is one 
of the key design aspects of an hMSC production process. For large‐scale processes, bead‐to‐
bead transfer strategies are necessary and should be promoted by the microcarrier. Several 
microcarrier types are commercially available, and a suitable microcarrier must be selected 
for each application by considering a combination of factors based on the following list of 
properties:
 – geometry, size and size distribution, porosity, physical density
 – GMP compliance
 – mechanical stability, autoclavable or sterile delivery
 – core and surface material (glass, polystyrene, gelatin, dextran, protein or synthetic protein 
fragments), source, surface characteristics (charge, stability, transparency, attachment and 
harvest, thermosensitivity)
 – compatibility with downstream processing
Some commercially available microcarriers have been developed to improve cell attachment 
using new synthetic or natural materials, whereas others are optimized for the specific harvest 
requirements of hMSCs [35]. Nonporous microcarriers are most suitable for hMSC expansion 
and harvest because successful detachment with high viability is difficult to achieve using 
porous microcarriers [36].
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2.2.3. Cell expansion in bioreactors
The reproducible, cost‐efficient, scalable and automated production of hMSCs in a dynamic, 
three‐dimensional system is best achieved using microcarriers because they allow controlled 
inoculation, expansion and cell harvest with the system remaining closed [37]. According to 
PAT requirements, control loops should include for example pH, temperature, stirrer speed or 
flow rate, aeration and feeding rate. Online process monitoring is necessary to ensure quality 
throughout the process, e.g., cell density, media properties (pH, temperature, pO
2
 and pCO
2
) 
and the concentration of metabolites such as glucose, lactate, ammonia and glutamine. The 
number of parallel systems should be minimized, aiming to achieve a high surface‐volume 
ratio, which can be realized using systems compatible with microcarrier cultivation. Sterility 
must be guaranteed by minimizing the contamination risk, and single‐use equipment is an 
option to achieve this. The system must allow low‐shear oxygenation by internal or external 
aeration, and a homogeneous nutrient supply, which are also required for PAT. Well‐char-
acterized systems are favorable because they facilitate process validation. Furthermore, the 
systems should be as simple as possible to avoid errors during system handling.
Several bioreactor types have been described for the expansion of hMSC and hMSC‐TERT cells. 
The most common are spinner flasks, stirred tank reactors (STRs), wave systems [38], fixed‐bed 
reactors (FBRs), fluidized bed and wall‐rotating systems [22, 39–41] as well as the application 
of Vertical‐Wheel™ technology [42]. Most published studies describe cell expansion in spinner 
flasks, but these are difficult to scale up and automate, and the only process control options are 
pH and oxygen concentration monitoring. Similar drawbacks are associated with wave reac-
tors. The most promising systems are STRs and FBRs. STRs are well‐characterized, scalable and 
controllable systems that are suitable for automation, whereas FBRs avoid the need for media 
replacement and also offer the opportunity to combine inoculation, expansion and harvest in 
one system [43–45].
Once the bioreactor system is chosen, the cultivation procedure and process parameters must 
be defined. The choice of the process mode strongly influences the process parameters, which 
must be adapted to achieve the defined product specifications [39]. Batch processes are often 
successful, but fed‐batch processes in STRs are more efficient and can be achieved by the par-
tial addition of media and microcarrier [40, 46]. The microcarrier concentration or bed volume 
must be chosen in combination with the seeding density, followed by the appropriate inocula-
tion strategy. The seeding density affects cell proliferation, and lower densities (100 cells/cm2) 
are more suitable than higher densities (5000 cells/cm2) [47], suggesting that a ratio of five cells 
per bead is optimal [48]. The dispersal of cells on the microcarrier follows a Poisson distribu-
tion [49]. Initial seeding densities of 1–3 × 104 cells/cm2 are nearly independent from the avail-
able growth surface area. The inoculation strategy is often based on intermittent agitation or 
flow depending on the system [50, 51].
The rotation speed of a STR is a critical process parameter because the culture should be 
homogeneous but a low shear stress is necessary to avoid changes to the cell characteristics 
while at the same time avoiding the formation of bridges between microcarriers by over-
growth [40]. This topic has been reviewed in detail [22, 52]. One solution is to increase the 
agitation rate during cultivation [53]. The application of a suspension criterion [54] may also 
New Insights into Cell Culture Technology104
facilitate process development and scale‐up, using theoretical process analysis based on 
power input, microcarrier type and cell growth. Three‐phase systems, such as aerated micro-
carrier‐based stirred‐tank cultures, show the complex effects of the working volume, carrier 
concentration and aeration on the power input. Understanding the mixing characteristics of 
such a system is required to optimize hMSC cultivation [55]. Similarly, for hollow fiber or 
FBR systems, the flow rate must be defined according to the cell line, microcarrier and sys-
tem volume [43]. Media exchange is often necessary to avoid nutrient limitation and critical 
metabolite concentrations [49], but only partial replacement is possible [56] and this increases 
the risk of contamination.
2.2.4. Cell harvest
Because the cells are the product, adherent hMSCs must be detached and separated from 
their growth surface. Unlike standard processes, where the cells do not need to be detached, 
harvest is a very sensitive process step but must still remain cost‐effective and GMP compli-
ant. In static cultures, cell detachment is often achieved using peptidases, usually trypsin (EC 
3.4.21.4), which cleaves peptide chains after most basic amino acids [57]. Cell detachment in 
dynamic systems is more complex, especially in terms of shear forces. Therefore, the enzyme 
used to detach cells grown on carriers in dynamic systems must be both gentle and efficient. 
The molecular basis of cell attachment depends on the microcarrier, so the choice of enzyme 
for detachment must take this into account. Furthermore, animal‐derived enzymes such as 
pancreatic trypsin should be avoided [58, 59]. Further aspects that must be addressed include 
the commercial availability of the enzyme, the final cell density, the incubation time and the 
temperature. The aim is to maximize the harvest yield and cell viability while maintaining the 
characteristics of the cells after harvest, processing and formulation.
2.3. Process requirements—downstream
2.3.1. Cell separation, clarification and concentration
After cell detachment, the carrier must be separated from the cells, followed by cell clarifica-
tion, washing and cell concentration (volume reduction) [60, 61]. For this part of the pro-
cess, large‐scale applications are still in their infancy. Appropriate methods, such as filtration, 
must ensure minimal processing time and must be based on inert, single‐use materials. Cell 
recovery must achieve clarification and volume reduction while preserving cell viability and 
retaining cell characteristics. Thus, low shear processes are necessary. Impurities must be 
reduced to levels below 1 ppm. The system should be closed, automated and scalable [62].
For standard biopharmaceutical processes, tangential flow filtration (TFF) [63] is often used 
for the initial clarification of therapeutic proteins produced in mammalian, bacterial or yeast 
cell cultures [64]. For the production of ATMPs, TFF processes must be redesigned to meet 
product quality demands. The filter material, pore size and initial cell concentration, as well 
as operating parameters such as shear rate and permeate flux, may influence the recovery of 
viable, high‐quality cells [63]. The impact of shear rate and shear stress on the viability and 
differentiation potential of hMSCs is well‐characterized [65, 66]. High shear rates are known 
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to reduce membrane fouling during microfiltration [67], so a trade‐off between fouling and 
cell damage is necessary to achieve a satisfactory hMSC concentration.
2.3.2. Formulation and storage
Allogenic stromal cells should be off‐the‐shelf products available on demand, and appropri-
ate formulation strategies are therefore required allowing the cells to be stored for a specific 
period of time under defined conditions. Often, allogenic cells are formulated as cell suspen-
sions. Alternative formulations, which prevent immune responses in recipient patients, are 
cell encapsulation. Inert and biocompatible materials, capsule size and a gentle encapsula-
tion process must ensure that cells retain their viability, identity, purity and differentiation 
capacity.
The same requirements are relevant to the storage method, including the physical storage 
form, long‐term product stability/availability and the eventual application of the stored cells 
to the patient, ideally without prior treatments. The storage form must also fulfill GMP and 
especially ATMP requirements. One common way to store cell culture and ensure long‐term 
availability is cryopreservation in liquid nitrogen. Post‐thaw cell survival is sensitive to the 
freezing and thawing processes, which require cryoprotective agents (CPAs) to prevent the 
formation of intracellular and extracellular ice crystals that would otherwise expand and 
destroy cell and organelle membranes [68, 69]. CPAs also minimize osmotic effects that would 
promote the denaturation of proteins [70]. The nature of the freezing and thawing cycle and 
the most appropriate CPA must be determined on a case‐by‐case basis for each cell line [71]. 
A detailed description of the development of cell line‐dependent cryopreservation protocols 
has been published [72] and the topic has been recently reviewed [73].
A storage system in a GMP environment features a constant temperature in a controlled and 
monitored environment with a barcode‐based vial‐labelling system. Frequent thawing of the 
frozen vials and testing according the above‐mentioned aspects are essential to ensure long‐
term stability.
3. Stem cell production in dynamic bioreactors
3.1. Media choice
As stated above, animal‐derived raw materials should be avoided and SFM, XFM or prefer-
ably CDM should be used for hMSC expansion. Appropriate media are available from several 
commercial sources (Table 1) and studies published between 2011 and 2015 using these dif-
ferent media for the cultivation of hMSCs have recently been reviewed [74].
Human platelet lysate has been used as an alternative for bovine serum by several groups, e.g., 
for umbilical cord‐derived hMSCs [75, 76]. XFM containing a mixture of proteins including 
human serum albumin and recombinant growth factors was used to expand hMSCs derived 
from bone marrow (bm‐hMSCs) and adipose tissue on microcarriers [77] and a similar approach 
with a XFM containing components from human plasma has also been described [78].
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Product name Company Classification and comments
(if information available by manufacturer)
The literature
and website
CellGro® MSC Medium CellGenix SFM: albumin (human‐plasma‐derived)
insulin (human recombinant, yeast‐derived),
synthetic lipid contains chicken egg‐derived lecithin 
(licensed medicinal product for human use)
Not cited
Web: [136]
CTS™ StemPro® MSC SFM Gibco by 
Thermo 
Scientific
SFM: coating with CELLstart™ CTS™ necessary [77, 137, 138]
Web: [139]
hMSC High Performance 
Media Kit XF
RoosterBio XFM: standardized, “enriched” basal medium Not cited
Web: [140]
Human MSC medium, 
chemically‐defined
AmCell 
Biosciences
recXFM: components are either chemically synthesized 
or recombinant produced and purified, none of its 
ingredients are directly derived from nonhuman animals
Not cited
Web: [141]
Mesenchymal Stem Cell 
Growth Medium DXF 
(Defined Xeno Free)
PromoCell XFM
fibronectin‐coated plates are necessary
[142]
Web: [143]
Mesenchymal Stem 
Cell Medium—animal 
component free (MSCM‐acf)
ScienCell 
Research 
Laboratories
XFM: no animal‐ or human‐origin materials.
Contains (quantitatively and qualitatively formulated) 
growth factors, hormones and proteins
Not cited
Web: [144]
MesenCult™‐XF Medium STEMCELL 
Technologies
SFM used in conjunction with the MesenCult™‐SF 
Attachment Substrate
Not cited
Web: [145]
MesenGro® Human MSC 
Medium
System 
Biosciences/
StemRD
recXFM: does not contain animal‐derived components, 
components are either chemically synthesized or 
recombinantly produced and purified
Not cited
Web: [146]
MSC NutriStem® XF 
Medium
Biological 
Industries
XFM, defined formulation. Use of fibronectin coating is 
recommended. Drug Master File available
[11, 147]
Web: [148]
MSC‐GRO™ Serum‐Free/
Xeno‐Free, Complete Media
Vitro 
Biopharma
XFM Not cited
Web: [149]
PowerStem MSC1 PAN‐Biotech XFM: free of animal or human serum, without animal 
derived components, no undefined peptones or 
hydrolysates, contains hormones, growth factors and 
enriched human proteins and lipids
Not cited
Web: [150]
PRIME‐XV® MSC Expansion 
SFM
Irvine 
Scientific
SFM: pre‐coated with PRIME‐XV MatrIS F necessary [100, 151]
Web: [152]
SPE‐IV Media ABCell‐Bio SFM: animal protein‐free, contains human albumin, 
synthetic iron carrier, rh‐insulin, nucleosides, α‐
monothioglycerol, synthetic lipids, rh‐IGF‐1 and rh‐b‐
FGF. Requires the addition of pre‐adhesion molecules 
such as fibronectin and collagen
Not cited
Web: [153]
Stem Cell 1 Cell Culture 
Technologies
CDM: chemically defined, protein/peptide‐free [35]
Web: [154]
StemMACS MSC Expansion 
Media Kit XF
Miltenyi 
Biotec
XFM Not cited
Web: [155]
StemXVivo Xeno‐Free Human 
MSC Expansion Media
R&D Systems XFM
coating with recombinant human fibronectin necessary
[138]
Web: [156]
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A new CDM for hMSC expansion has been described in which each component has a 
Chemical Abstracts Service (CAS) registration number and none of the components  frequently 
used in XFM formulations are present, such as serum albumin, insulin, transferrin, proges-
terone, hydrocortisone or estradiol [35]. The absence of attachment‐promoting factors limits 
the attachment behavior of the hMSCs and the growth surface must therefore be coated with 
attachment‐promoting substances. To our knowledge, this stem cell 1 medium (Cell Culture 
Technologies, Switzerland) is the only protein/peptide‐free CDM for hMSC expansion, mainly 
comprising defined concentrations of low‐molecular weight compounds (50–250 Da, with 
only one component larger than 1000 Da). The addition of recombinant growth factors in 
combination with surface coatings makes this medium suitable for the attachment, spreading, 
growth and detachment of hMSCs derived from different tissues [35].
3.2. Microcarrier choice
Several commercial microcarrier products are available that are suitable for hMSC expansion, 
as recently reviewed [34]. Microcarriers with surfaces comparable to static tissue culture plas-
tic simplify the transfer of cells from static to dynamic cultivation environments. They have 
been used successfully for bm‐hMSCs in a 5 L STR [79]. Microcarriers 2–5 mm in diameter are 
often used for FBR processes, whereas those used in fluidized bed reactors are typically 1 mm 
in diameter and those used in STRs are generally 100–300 µm in diameter [80]. Glass has been 
used as a cell culture growth surface for decades [81], and low‐density microcarriers with a 
copolymer plastic core and a high‐silica glass coating were used for the expansion of hMSC‐
TERT in serum‐containing medium [51, 82]. These results are based on a microcarrier choice 
for the hMSC‐TERT cell line resulting in strong proliferation and a good yield of detached 
cells for glass and polystyrene microcarriers [36].
Microcarriers should be selected on a case‐by‐case basis. For example, glass‐coated and plastic 
microcarriers both achieved comparable maximum cell densities (0.91 × 104 and 1.08 × 104 cells/
cm2, respectively) for umbilical cord‐derived MSCs expanded in XFM [75] but only the plastic 
microcarrier achieved an even distribution of cells (75% of carriers occupied after 72 h), which 
is essential for successful process scale‐up.
Microcarriers coated with extracellular matrix proteins (ECMs) such as collagen can also be 
used for hMSC expansion [83]. The ECM components encourage cell attachment and growth 
by providing adhesion ligands on the surface. As discussed above, animal‐derived proteins 
Product name Company Classification and comments
(if information available by manufacturer)
The literature
and website
TheraPEAK™ MSCGM‐
CD™ Mesenchymal Stem 
Cell Medium, Chemically 
Defined
Lonza XFM: contains only constituents of known molecular 
structure, contains human albumin, recombinant human 
insulin, pasteurized human transferrin
[25, 157, 158]
Web: [159]
Table 1. Overview of commercially available, SFM and XFM for the cultivation of hMSCs (as of July 2016).
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are discouraged because they increase the risk of contamination and the composition is 
unpredictable, causing a lack of reproducibility. Microcarriers are therefore coated with syn-
thetic protein fragments. For example, Synthemax microcarriers (Corning) achieved yields 
and metabolite profiles in bm‐hMSC cultures that were comparable to collagen‐coated micro-
carriers [84]. They are suitable for XFM applications [78], as are microcarriers with plasma‐
treated plastic surfaces that show improved hydrophilicity and wettability to encourage cell 
attachment [85].
3.3. Stem cell expansion
The following sections focus on the expansion of hMSCs and hMSC‐TERT cells using STR and 
FBR systems due to the limitations of the other systems described above. We consider PAT 
applied in STR and FBR systems and the use of disposable bioreactors.
3.3.1. PAT applications
In basic processes, the pH, temperature and oxygen partial pressure are monitored to ensure 
quality throughout the process. In more advanced processes, the concentrations of cells, sub-
strates and metabolites can also be measured. Online monitoring tools are ideal, but offline 
data analysis is needed for correlation. The cell density on a microcarrier is often determined 
offline by cell lysis followed by counting the released nuclei, but this is rather imprecise [86]. 
Alternatively, an intercalating fluorescent dye such as SybrGreen I can be used to estimate 
DNA levels, which are linearly related to the cell density, and this can be achieved without 
cell detachment [86]. Dielectric spectroscopy is a promising tool for the online measurement 
of cell density [21, 86, 87]. At a frequency of 300 kHz, there is a linear correlation between the 
permittivity and the cell density up to 5 × 104 cells/cm2 (∼80% confluence). This is sufficient 
because cell confluence should not be reached. The cell adhesion process can be monitored 
analyzing the critical frequency. As the cell volume changes during adhesion, the critical 
frequency declines and remains almost constant throughout the exponential growth phase. 
When monitoring a process limitation such as oxygen depletion, the permittivity of the cells 
changes and this is clearly shown in the signal [39, 86]. If the introduction of a probe is not 
possible (e.g., in FBR processes), the cell density can be determined indirectly, e.g., by calcu-
lation from the oxygen or substrate consumption. Mid‐infrared spectroscopy combined with 
multivariate data analysis is another promising online tool to optimize process monitoring 
for spinner cultures, particularly in the context of process prediction, contamination risks, 
speed and economic modeling. An optimized partial least squares regression model has 
been used to estimate glucose, lactate and ammonia concentrations [88].
3.3.2. Fixed‐bed reactor
FBR systems can be automated, but it is not possible to take samples, so the cell density 
is determined indirectly by measuring glucose or oxygen consumption. The homogeneity 
and scalability of FBR systems remain challenging despite intensive development work by 
Weber and colleagues [43, 44, 89, 90] and by Elseberg [39]. In bed volumes of 14–300 mL, 
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2 mm diameter solid glass carriers [91] were successfully used to cultivate hMSC‐TERT 
cells in Eagle's minimal essential medium (EMEM) with serum. The inoculation strategy 
was 4 × 30 min for each 7 min with 2 × 104 cells/cm2 at a superficial velocity of 0.48 cm/min, 
achieving an inoculation rate of 50%. During expansion, the superficial velocity was 1.6 cm/
min. Process monitoring involved online oxygen measurement (>60%) as well as pH (7.4) 
and temperature (37°C) control in the conditioning vessel. The system was integrated into a 
process control system (Figure 2).
Offline measurements of glucose and lactate concentrations were used to determine the cell 
density. Partial media replacement was carried out at glucose concentrations below 0.4 g/L. 
Expansion was defined as complete at a cell density of 5–5.5 × 104 cells/cm2. Analysis of resi-
dence time in the 300 mL reactor during cultivation clearly showed an inhomogeneous cell 
distribution, which caused an altered flow profile [39]. Shear stress (1.74 × 10-6 N/cm2) was 
below the critical value of 1.5 × 10‐4 N/cm2 [66]. In summary (Figure 3), cultivation for 8 days, 
starting with 1.2 × 104 cells/cm2, achieved a final cell density of 6.3 ± 0.86 × 104 cells/cm2 (total 
per batch of approximately 3.16 × 108 cells for 5500 cm2) at an average growth rate of 0.27 d-1 
[39]. Complex models and scale‐up considerations have been published [44]. Monod‐based 
models showed that the glucose uptake rate, and therefore the cell density calculation, 
Figure 2. Schematic drawing of the expansion and harvest process for hMSC‐TERT cells in a 300 mL bed. Peristaltic 
pumps and hose‐crushing valves ensured process flow and switching. Single‐use oxygen sensors were introduced 
before and after the packed bed. To avoid carrier settling below the bed, a sieve with a mesh size of 100 µm was inserted 
at the bottom socket. D1: heating blanket, G1: harvest vessel, G2: buffer vessel, G3: waste vessel, G4: enzyme vessel, 
G5: reservoir, I1: pH‐probe, I2: pO
2
‐probe, I3: temperature probe, I4‐I5: pO
2
‐probe, I6: temperature probe, I7: dielectric 
spectroscopy, I8: mass determination, K1: measurement chamber, M: motor, P1‐P2: pump, R1: packed‐bed reactor, R2: 
conditioning vessel, T: water bath for constant temperature, V.1‐V.8: valves, W: balance [39].
New Insights into Cell Culture Technology110
depends on the number of passages and the scale. The system could potentially be improved 
to achieve a more homogeneous cell distribution by optimizing the inoculation strategy.
Placenta‐derived hMSCs have been cultivated in a scalable packed‐bed reactor in which the 
13 mL bed was encased within a gas‐permeable shell for indirect aeration and nutrient sup-
ply [92]. This achieved a low shear of 9.5 × 10‐5 Pa at a flow rate of 5 mL/d. The growth sur-
face (160 cm2) was provided by air plasma‐treated polystyrene pellets endowed with a surface 
chemistry similar to tissue culture plastic. A 10‐fold expansion of initially 1 × 104 cells/cm2 in 
Dulbecco's modified Eagle's medium (DMEM) with serum was achieved after 1 week in cul-
ture, and the cells retained their differentiation capacity. Even so, cell growth in the packed bed 
culture was slower than growth in static two‐dimensional cultures. Inoculation was performed 
by rolling the column at 5 rpm for 5 min then resting for a period of 3 h. The cell density was 
determined by AlamarBlue staining, which caused cell disruption. The system was shown to 
be scalable and suitable for the automated cultivation of murine MSCs to a volume of 235 mL 
and a growth surface of 2800 cm2 and therefore appears suitable for hMSC expansion [92].
3.3.3. Stirred tank reactor
Intensive work on the development of a hMSC‐TERT batch process in a 3 L glass STR 
with a working volume of 1.65 L was described by Elseberg and colleagues, and the cell 
 characteristics were retained [39, 51]. The sterilized bioreactor (Figure 4) was filled with 
the sterile glass‐surface microcarrier RapidCell [36] at 25 g/L suspended in high‐glucose 
DMEM supplemented with 10% serum [51]. Cell suspensions were introduced by a syringe 
at a density of 7 × 103 cells/cm2 in four cycles, comprising 45 min without stirring and 2 min 
Figure 3. Cell and substrate concentration during hMSC‐TERT expansion in a 300 mL fixed‐bed bioreactor [39]. Model 
data are based on an initial cell concentration of 1.45 × 107 cell/mL and 0.9 g/L initial glucose concentration using the 
Euler‐method for first order kinetics.
The Challenge of Human Mesenchymal Stromal Cell Expansion: Current and Prospective Answers
http://dx.doi.org/10.5772/66901
111
with stirring at 120 rpm [51]. The process parameters pH (7.4), temperature (37°C) and pO
2
 
(<60%) were monitored online, the cell density determined by dielectric spectroscopy. The 
fluorescence‐based assay described above was used offline to determine cell density, com-
bined with microscopy. During  expansion, the rotation speed was increased stepwise from 
120 to 160 rpm at 10‐rpm intervals for every 1.2 × 104 cells/cm2 [51]. The cultivation data con-
firmed that the cell density, substrate consumption and metabolite production were repro-
ducible, and critical values of lactate and ammonia concentrations were not observed. In 
summary (Figure 5), after 6 days of cultivation, starting at 7 × 103 cells/cm2, a final cell density 
of 4.5 × 104 cells/cm2 was achieved (equivalent to ∼6.84 × 108 cells for a surface of ∼13,600 cm2) 
with an average growth rate of 0.32 d-1 in three replicate cultivations [39]. The detailed proto-
col has been published [93]. Optimization studies should consider bead‐to‐bead transfer as a 
stepwise fed‐batch process to reduce costs. Furthermore, the online analysis of glucose and 
lactate would be beneficial. The detailed analysis of each step may also allow the process to 
be adapted for primary cells.
One of the larger‐scale processes for hMSC production (2.5 L in a 5 L STR) [79] required a 
cultivation time of 12 days to achieve a cell density of 1.7 × 105 cells/mL. The culture conditions 
were pH 7.2–6.7 at 37°C and pO
2
 >45%. This allowed a sixfold expansion while retaining cell 
characteristics. Oxygenation only occurred during 50% media exchange every second day after 
day 3. The inoculation density was 6 × 103 cells/cm2 on plastic‐surface microcarriers (P102L by 
Solohill), which is equivalent to ∼5 cells/bead. The static culture with a down‐pumping impel-
ler was run in static mode for 18 h at 75 rpm to ensure that all microcarriers were distributed 
Figure 4. Schematic drawing of the expansion process for hMSC‐TERT cells in a 3 L glass STR including a picture of 
SybrGreen‐stained hMSC‐TERT cells on RapidCell microcarriers; D1: heating blanket, I1: pH probe, I2: pO2 probe, I3: 
temperature probe, I4: dielectric spectroscopy, M: motor, R: glass stirred tank reactor, V1: valve [39].
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evenly throughout the reactor, resulting in better cell growth compared to spinner cultures. 
The authors found that homogeneity could be achieved with less power input compared to 
the spinner cultures. Optimization was required in terms of pH and oxygen control, as well as 
monitoring the cell density to determine the point of confluence during the process.
A further process has been described for hMSCs in a 1.3 L working volume STR [94]. The 
expansion processes differed according to the source of the hMSCs, such as umbilical cord 
matrix‐derived hMSCs (UCM‐hMSCs), highlighting the need for tailored process develop-
ment. The cultivation of UCM‐hMSCs was recently demonstrated using gelatin‐based micro-
carriers and XFM in a controlled STR culture with a working volume of 800 mL [41]. To 
increase process efficiency, an automated continuous process (e.g., without  intervention for 
media replacement) was developed based on continuous perfusion in a STR and the cells 
retained their differentiation capacity [95]. Starting with 0.25 × 105 cells/mL in 400 mL at 
40–60 rpm in Mesencult™‐XF media, continuous perfusion was carried out including a cell 
retention device, such as the ATF‐System for microcarriers by Repligen Corporation, with 
dilution rates of 0.2 d-1 starting on day 5, or a dip‐tube adapter attached to the bioreactor cap. 
Inoculation was achieved by intermitted stirring on Synthemax II microcarriers at 16 g/L. This 
resulted in higher cell densities of 3.7 × 105 cell/mL (expansion ratio = 14.6) and growth rates 
of 0.016 h-1. No media depletion was observed, and inhibitory substances such as lactate and 
ammonia remained below critical values of (<6 and <1 mM, respectively [50]). Bead‐to‐bead 
transfer was further shown to increase process efficiency by the addition of empty microcar-
riers on day 6 [78].
Single‐use technology is appropriate for economic reasons and to meet GMP requirements 
because this eliminates the risk of cross‐contamination and facilitates the validation and 
Figure 5. Cell density and substrate concentration during hMSC‐TERT expansion in a 3 L glass STR [39]. Model data are 
based on an initial cell density of 4.24 × 107cell/mL, and 3.5 g/L initial glucose concentration using the Euler method for 
first order kinetics.
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 qualification of the system. The first disposable STR used for the expansion of hMSCs on 
microcarriers was the Mobius® 3 L bioreactor by Merck‐Millipore with 2.4 L working vol-
ume, which yielded ∼600 million hMSCs on collagen‐coated polystyrene microcarriers [83, 
96]. The cells retained their basic defining characteristics, i.e., cell surface marker expression 
and differentiation potential. The cultivation of hMSCs over 12 days in this system was com-
patible with bead‐to‐bead transfer. This increased the expansion factor to 62‐fold, six time 
higher than a normal batch process, achieving a yield of 49,750 cells/cm2. Starting with a 
growth surface of 5400 cm2, the addition of media and microcarrier after 7 days increased 
this to 10,800 cm2 (+1 L) and 12,960 cm2 on day 11 (+0.4 L) until the end of the process. This 
process involved non‐cycling inoculation at 35 rpm. During cultivation, the stirrer speed was 
increased from 55 to 75 rpm and minimal aggregate formation was observed [46]. The mixing 
characteristics of this three‐phase system showed a certain degree of inhomogeneity, but this 
was beneficial because the cells were allowed rest phases of low shear stress [55].
The transfer of a process for hMSC‐TERT cells from a geometrically similar glass STR to the 
single‐use Mobius® 3 L bioreactor has also been described [51]. All parameters were kept 
constant except the stirrer speed, which was reduced to 60–90 rpm, achieving a 6.9‐fold 
expansion and comparable growth rates to the glass STR. Even so, carrier aggregation was 
observed, indicating nonoptimal culture conditions [46]. Other systems include the 1.3 L 
Bioflo® by Eppendorf for the production of 1.4 × 105 cells/mL, which is also available as a 
single‐use device [77]. The UniVessel® by Sartorius for hMSC cultivation can produce up to 
1.8 × 105 cells/mL in a maximum volume of 2 L [22]. The cell density can be increased by up 
to three‐fold by reducing shear forces, which can be achieved by changing the impeller blade 
angle from 30° to 45°, reducing the off‐bottom clearance from 0.411 to 0.26 and increasing the 
microcarrier density. To our knowledge, the largest volume for hMSC expansion used the 
BIOSTAT® CultiBag STR 50 L with 5% serum‐supplemented stem cell media by Lonza [22, 
54]. Inoculation was implemented during a 4‐h cell attachment phase in 20 L of medium‐con-
taining equilibrated gelatin microcarriers, and the bag was then transferred to the CultiBag 
STR 50 L starting with a 35 L working volume. The process conditions were 37°C, pO
2
 >20%, 
maximum air flow rate of 0.03 vvm, pH 7.2–7.3 and the impeller speed was set to 50–66 rpm. 
The peak viable cell density was 7.2 × 105 cells/mL, with an expansion factor of 51.5 ± 4.9.
3.4. Cell detachment
As described in Section 2.2, enzymatic cell detachment is often a crucial step for the successful 
production of hMSCs. Researchers often use recombinant trypsin for process development, 
but there is an intensive ongoing search for alternatives, mostly studied using static cultures 
[82]. Here, we discuss the harvesting procedure for the dynamic systems described above and 
then consider alternatives based on studies using static cultures.
Studies reported by Weber [89] and Salzig and colleagues [82] have shown how cells can be 
harvested from a FBR system. Success depends on the combination of enzyme choice, incuba-
tion time and temperature, and the effects of downstream processing and formulation [82]. 
After flushing the reactor twice with phosphate buffered saline (PBS), harvesting was carried 
out by incubating the cells with TrypZean for 15 min at 21°C and cells were flushed out of 
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the reactor with media (37°C) at a superficial velocity of 19 cm/s. The yields were not repro-
ducible due to the inhomogeneous cell and enzyme distribution, and the highest yield was 
82.1 ± 2.3%. The final cell density had a strong impact the cell harvest yield. Based on transport 
limitations, higher cell densities reduced the viability of the cells from 80–90% to 50% [39].
In a glass STR process [39, 46, 51, 93], a partial cell harvest of 300 mL was achieved using a 
sieve with a mesh size of 100 µm to separate the carriers with the cells from the media. The 
carriers were then rinsed with PBS and the entire sieve was transferred into a dish containing 
trypsin solution for incubation at room temperature for 10 min. Detached cells were rinsed 
off with serum‐containing media. This method achieved a consistent high harvest yield with 
>95% cell viability. The viability, metabolic activity (determined with water‐soluble tetrazo-
lium salt) and adipogenic differentiation capacity of the cells were comparable to cells from 
static cultures in T‐flasks, whereas cell growth of re‐cultured cells was slightly slower.
A potentially scalable harvesting method has been developed to recover hMSCs from a 5 L 
STR with a working volume of 2.5 L, based on studies in spinner flasks with plastic‐surface 
microcarriers [97]. The duration of the incubation step in trypsin‐EDTA was limited to 7 min 
and combined with agitation (150 rpm) so that Eddy sizes exceeded the cell size. The harvest 
efficiency was >95% with a viability of 98%, and cells retained their characteristics [18]. Cell 
harvest from a 5 L STR would normally require 8–9 min incubation with the enzyme and 
agitation at 120 rpm. Further studies are required to optimize the incubation time, taking 
into account carrier‐carrier effects, carrier density and the cell density prior to the harvest 
[97]. Other groups use the nonmammalian trypsin TrypLE for the detachment of hMSCs [94, 
97–100] on cationic polystyrene charged microcarriers, which achieves high cell quality even 
in cultures based on SFM [63, 100].
A promising and safer alternative to trypsin is the prolyl‐specific peptidase (PsP) expressed 
natively and isolated from the fungus Wolfiporia cocos [58]. Allogenic hMSC‐TERT cells were 
detached more rapidly with 1.6 U/mL PsP than trypsin, and the new enzyme also showed less 
severe effects on the growth and metabolism of re‐cultivated cells. The optimal harvest yield 
was achieved by incubating the cells in PsP for 20 min.
Studies using static cultures have shown that the choice of the enzyme must be considered 
in combination with the growth surface coating and the type of medium for each cell type on 
a case‐by‐case basis [35]. The authors compared the detachment of hMSCs and hMSC‐TERT 
cells with trypsin, Accutase, collagenase and PsP when the cells were grown on untreated 
surfaces, or surfaces coated with collagen or fibronectin, combined with CDM or serum‐con-
taining media (SCM). These different conditions had a significant impact on the detachment 
of hMSC‐TERT cells but little impact on primary hMSCs, although the detachment of hMSCs 
was slightly less in the absence of coatings (Figure 6). All detached cells remained highly 
viable [35].
For gelatin‐based microcarriers, the total digestion of the microcarrier is possible using tryp-
sin, yielding a single‐cell suspension. Although this removes the need for cell‐carrier separa-
tion, a longer incubation time is necessary which can change the immunophenotype of the 
cells, but this can be reverted during re‐cultivation in static cultures [41].
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A promising alternative is the use of thermosensitive microcarriers to avoid the need for enzy-
matic cell detachment. Various materials have been tested, i.e., poly‐N‐isopropylacrylamide, 
and recently, a successful application has been reported in dynamic systems [101–103]. 
Although proteolytic enzyme treatment is not necessary, mechanical forces are still required 
to achieve a single cell suspension, as cell‐cell‐contact is not dissociated due to the tempera-
ture shift [104]. Future research in this area could offer a replacement for the gold standard of 
cell detachment with trypsin or its derivatives, particularly if combinations of enzymes and 
functional surfaces are considered.
Figure 6. Detachment of hMSC‐TERT cells using different enzymes for n = 3 measurements each. The cells were grown 
to confluence in coated or uncoated wells and were detached enzymatically. Cell detachment was analyzed by counting 
the cells in suspension [35].
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3.5. Separation, clarification and concentration
Until recently, the scalable harvesting of hMSCs has received little attention [63, 97]. The sepa-
ration of single cells from the carrier in STR systems can be achieved by dead‐end filtration 
[63, 97, 100]. The pore size of the polystyrene filters must be >75 µm to maintain cell viability 
and quality because hMSCs fall within the size range 15–20 µm, whereas the microcarriers 
are 125–212 µm [63]. Cells could also be harvested directly from a disposable STR by inserting 
a sieve [46]. Commercially available systems for cell‐carrier separation in general have been 
reviewed, and the authors also suggest the option of continuous flow centrifugation, which 
is available as a closed, single‐use device that can handle approximately 250 L of culture with 
15 g/L of microcarrier, but will require modifications for compatibility with ATMPs [40].
For FBRs and the glass STRs described above [39, 51, 89], cell‐carrier separation is achieved 
by flushing the cells from the bioreactor when enzymatic detachment is complete. The shear 
forces during this process transiently exceed the critical value of 1.5 × 10‐4 N/cm2, which may 
explain the loss of cell viability. The integration of a measurement chamber including a dielec-
tric spectroscopy probe allowed the definition of parameters that maximized the harvest yield 
while minimizing the volume. Concentration was achieved by centrifugation and resuspen-
sion in a smaller volume [39]. For cells harvested from the FBR process described above, cells 
retained their capacity for adipogenic differentiation and their metabolic activity was only 
slightly lower than cells cultured in parallel using T‐flasks. Cells harvested from the STR 
process after centrifugation consistently showed >90% viability, comparable to cells in static 
cultures in the same medium [39].
Clarification and volume reduction can be achieved not only by centrifugation [100] or dead‐
end filtration [105] but also by TFF to achieve better product purity [63, 106]. Many fully auto-
mated, disposable and integrated (concentration and washing) TFF systems are available that 
are compatible with ATMP processes. TFF systems have linear scalability and operate with 
low shear forces and pressures. A TFF system with hollow‐fiber modules and polysulfone 
membranes (24 cm2 surface, pore size >45 µm, sterilized with NaOH) was recently used for the 
downstream processing of hMSC suspension cultures [63]. The authors showed that 10‐fold 
concentration in a 0.25 L volume is possible, removing 98% protein and maintaining >95% via-
bility as well as cell identity and potency, at a shear rate of 3000 s-1. The permeate flux was con-
trolled at 250 L m-2 h-1 and cell recovery was more than 80% at densities >2 × 105 cells/mL. The 
cell density, shear rate and permeate flux were shown to affect yield, viability and quality of 
the cells [63]. The incorporation of an expanded bed chromatography step using a multimodal 
prototype resin based on core‐shell bead technology achieved a further 10‐fold increase in effi-
ciency, with a process recovery of 70% in negative mode. The best trade‐off between cell recov-
ery (89%) and protein clearance (67%) was achieved using an intermediate expansion bed rate 
(1.4) which also retained the cell characteristics. A further diafiltration step can be introduced 
using a CPA solution for formulation, fill and finish [95]. This reduces the overall diafiltration 
volumes and achieves a product purity sufficient for clinical applications. TFF combined with 
negative mode chromatography may therefore represent the beginning of a new generation of 
downstream processes for hMSCs that can be improved further by the investigation of novel 
adsorbents [106]. The cost of large‐scale separation, clarification and concentration could be 
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reduced fluidized bed centrifugation [62], whereas TFF would be more appropriate for smaller 
lots. The raw materials and detailed process parameters must always be chosen according to 
the cell line, media, microcarrier and expansion process.
3.6. Formulation and storage of stem cells
As discussed above, cryopreservation is the standard storage mode for single‐cell suspen-
sions, and this is also the case for allogenic hMSCs [107]. The standard is a slow freezing rate 
of 1°C/min down to ‐80°C and a quick thawing rate (2 min at 37°C for 2 mL vials) using 5–20% 
dimethylsulfoxide (DMSO) in serum as a CPA [72]. Neither DMSO nor serum are suitable for 
ATMPs [69, 108]. For other stem cells, successful cryopreservation has been achieved using 5% 
DMSO in 5% human albumin [109]. A recently published study discussing the long‐term cell 
banking (up to 8 years) of allogenic hMSC used a cryopreservation method with 20% DMSO, 
and the cells were suitable for clinical studies within 1 h after thawing and dilution in PBS 
[110]. Sodium pentaborate pentahydrate combined with low concentrations DMSO is benefi-
cial for tooth germ stem cells [111]. SFM and XFM combined with 5–10% DMSO is suitable for 
different human progenitor cells [112]. Research is underway to find appropriate alternatives 
CPAs to avoid the need to remove DMSO (e.g., by diafiltration) before their use in the clinic.
Based on promising preliminary studies [69], ectoin and proline have been investigated as 
alternative CPAs for hMSC‐TERT cells [108]. They were compared to commercially avail-
able Biofreeze SFM lacking DMSO (Biochrom, Germany [113]) combined with methylcellu-
lose supplemented PBS. The cells were stored at ‐150°C and thawed quickly at 37°C. The 
highest cell survival rates after 48 h re‐cultivation (89 ± 2%) without DMSO and serum were 
achieved by supplementing the medium with 1%/10% (w/v) proline/ectoin for 60 min before 
freezing, and then reducing the temperature by 1°C/min which was shown to be beneficial 
for other stem cells [108]. The best results (∼99% survival rate) were achieved with Biofreeze 
SFM in all approaches. Regardless of whether Biofreeze or 1%/10% proline/ectoin was used, 
the cells retained their adipogenic differentiation capacity. The impact of the duration of pre‐
freeze incubation and the cooling rate depended on the CPA combination. To improve out-
come of cryopreservation, the authors suggested nucleation temperature control during the 
freezing process [108]. Another recent report described the formulation of hMSCs using the 
FDA‐approved commercial serum‐free and xeno‐free CPA known as STEM‐CELLBANKER™ 
(Amsbio, UK) [29]. The cell viability was >90% (better than DMSO) and no morphological dif-
ferences were observed, but cell growth was slower. The mesodermal differentiation capacity 
was not regardless of which CPA was used [29]. The cryopreservation of hMSCs has also been 
tested using Prime‐XV MSC FreezIS DMSO‐Free (Irvine Scientific, USA) with 30 min incuba-
tion at room temperature before cooling to 4°C for 5 min followed by further cooling at 1°C/
min down to ‐80°C for storage in liquid nitrogen vapor. The cells were thawed quickly at 37°C 
[100]. Other CPAs such as sucrose and high‐molecular‐weight polymers like polyvinylpyrolli-
done [114] should be investigated as well as studies in larger volumes or geometries (such as 
syringes) that might be more appropriate for therapeutic approaches [108].
In addition to single‐cell formulations, the encapsulation of cells may be beneficial to pre-
vent allogenic cells triggering an immune response in the patient [115–117]. A semi‐perme-
able membrane allows the diffusion of molecules (e.g., nutrients and therapeutic proteins) 
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but  protects the cells from the host immune system and mechanical forces, thus potentially 
enhancing the therapeutic benefits of hMSCs [118]. Various production methods have been 
tested to generate small beads (200–400 µm) with a narrow size distribution [119]. The for-
mation of core capsules is often suggested [120] and this can be used to induce line‐specific 
differentiation [22] even when cells are cultivated in a FBR [90]. Biopolymers such as agarose, 
Pluronic F‐127 [121] and clinical‐grade alginate are used for this purpose, the latter forming 
three‐dimensional structures in the presence of multivalent cations.
Cells harvested from FBRs or glass STRs can be encapsulated by suspending 5 × 106 cen-
trifuged cells in 500 µL sodium histamine solution then adding 4.5 mL sterile 1.5% algi-
nate solution. After incubation for 2.5 h, the suspension was dropped into a BaCl
2
 solution 
and incubated for 2 h. Finally, the capsules were washed at least three times with PBS, 
and twice with EMEM and cultured in six‐well plates for further analysis. Encapsulated 
cells from the FBR showed adipogenic differentiation capacity and high viability (80–90% 
decreasing after 48 h). Cells encapsulated from T‐flasks consistently showed vitalities 
>95% [39, 91].
The cryopreservation of encapsulated cells is useful for the long‐term storage and off‐the‐
shelf availability of many cell types, including hMSCs [122]. A three‐step slow cooling pro-
cess [123] with induced ice nucleation using 10% DMSO (also suggested elsewhere [124]) has 
been shown to maximize cell viability, and the cells retain their metabolic and differentiation 
capacity. Cell encapsulation may also be beneficial for short‐term storage, such as for trans-
port [125]. The hypothermic (4–23°C) preservation of human adipose‐derived cells encapsu-
lated in 1.2% alginate in XFM/SFM has been discussed [126].
4. Quality approval
Prior to the product release, intensive quality control is required to confirm cell identity and 
safety according to validated protocols that comply with GMP, the International Conference 
on Harmonization (ICH) Guidelines and/or the European Pharmacopoeia [17].
4.1. Identity
Cell identity must to be approved, including viability, differentiation capacity and the surface 
marker profile demanded by the ISCT [18]. Cell viability, metabolic activity and growth rates 
can be monitored during the production process after every step (after isolation, after expan-
sion, after harvest and clarification, after final formulation). Viability testing and cell counting 
are achieved using methods such as flow cytometry, including dye exclusion. Different dyes 
make it possible to detect viable and dead cells even in encapsulated formulations [82].
Immunophenotyping by flow cytometry is used to detect surface markers. Antibodies that 
bind to specific antigens expressed by the cell are coupled to fluorophores. A repertoire of cell 
markers can be identified and quantified simultaneously using different dyes. Many of the 
antigens used to distinguish human cell populations are cluster of differentiation (CD) mol-
ecules (www.hcdm.org). Immunophenotyping by flow cytometry has become the method of 
choice to identify and sort cells, e.g., in bone marrow aspirates.
The Challenge of Human Mesenchymal Stromal Cell Expansion: Current and Prospective Answers
http://dx.doi.org/10.5772/66901
119
The differentiation of hMSCs into osteoblasts, adipocytes or chondroblasts can be induced 
using established methods [127–129]. Several differentiation media are commercially avail-
able, although the ingredients are often not fully disclosed (e.g., StemPro® Differentiation Kits 
for hMSCs by Gibco). The multi‐step process of adipocyte development involves a cascade 
of transcription factors and cell‐cycle proteins that regulate gene expression. Adipogenesis is 
induced by insulin, dexamethasone, 3‐isobutyl‐1‐methylxanthine (IBMX) and indomethacin 
[130]. Differentiation towards the adipogenic lineage can be confirmed by Oil Red O staining 
of lipid vacuoles in the adipocytes. MSCs undergoing chondrogenic differentiation produce 
large amounts of ECM when cultured in pellet form, primarily composed of cartilage‐specific 
molecules such as collagen type II and aggrecan [129]. The latter can be used as evidence for 
the chondrogenic differentiation of hMSCs and can be stained with Alcian blue, or by the 
immunostaining of collagen type II. Osteogenic cells show changes in cell morphology, from 
spindle shaped to cuboidal, and the cells accumulate extracellular calcium deposits (mineral-
ization). Osteoblast mineralization is therefore indicative of the formation of bone mass and 
can be detected using the dye Alizarin Red S [127].
The successful differentiation of hMSCs and the expression of corresponding CD markers can 
also be verified by quantitative reverse transcription PCR (qRT‐PCR), which requires the extrac-
tion of RNA. Different protocols for RNA extraction from tissues are available, and commercial 
kits can be used to capture RNA on silica membranes in spin columns or isolate the RNA by 
phenol/chloroform extraction, followed by precipitation. A recently published study compares 
different single‐step RNA extraction methods focusing on embedded stem cells [131].
Lineage differentiation capacity needs to be approved only once for a validated process, if 
no further changes occur. A single‐cell preparation does not need to be re‐evaluated because 
the differentiation of cells in vitro takes 10–30 days, resulting in ethical discussions for on‐
demand product applications. Generally, the benefit‐risk ratio of clinical applications must 
also be considered [16].
4.2. Safety
The sterility of therapeutic hMSC products must be guaranteed because any contamination 
(bacteria, bacterial endotoxins, mycoplasma and viruses) present a high risk to the patient. 
Protocols for tests are provided in the European Pharmacopoeia (EuPh) chapters 2.6.27, 2.6.14 
and 2.6.2. The chapter on microbiological examination was revised in September 2016 [132]. 
This covers a selection of alternative tests because classical microbiological methods are often 
not suitable for products with a shelf‐life of only a few hours or a few days.
The potential tumorigenicity of therapeutic hMSC products is also relevant [133] but chromo-
somal abnormalities are rarely observed in freshly‐isolated primary hMSCs [134]. However, 
primary hMSC populations are heterogeneous, comprising cells of different ages that have 
undergone different numbers of divisions. The presence of abnormalities is dependent on 
both the donor and the in vitro culture method. In 2014, an investigation of 92 clinical‐grade 
bm‐hMSCs showed clonal mutations in only 3 of 86 cases, and none of these showed evi-
dence of a malignant transformation or a change in phenotype [135]. To exclude products 
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containing cells with cytogenetic abnormalities, G‐band karyotyping and fluorescence in situ 
hybridization (FISH) is necessary, as proposed by the EMA Cell Products Working Party 
(CPWP) and the Committee for Advanced Therapies (CAT) [133]. The cytogenetic testing 
of each batch as a release criterion is unnecessary if chromosomal abnormalities are not 
observed. The cryopreservation of batch samples during manufacturing is useful for later 
testing if needed.
5. Conclusion
The production of allogenic hMSCs is challenging, and there is intensive research focusing 
on the different steps in the process. Research institutes and industry have only recently 
published various reviews on this topic, and to our knowledge, there are still no large‐
scale processes with detailed protocols for every process development step, from cell line 
and media selection through to the final formulation and storage, focusing on the special 
demands of ATMP production. This chapter has summarized the major issues affecting 
such a process and has discussed potential future options. Further research is required to 
develop closed, continuous and efficient processes that meet regulatory demands for high 
product quality.
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